Please login to the form below

Not currently logged in
Email:
Password:

IL-17 inhibitor

This page shows the latest IL-17 inhibitor news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... In the case of psoriasis, that includes not only new therapies such as Novartis’IL-17 inhibitor

Latest news

  • UK, Germany back routine use of J&J’s Tremfya UK, Germany back routine use of J&J’s Tremfya

    psoriasis therapies such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab), which EvaluatePharma expects to become a $4.6bn product by 2022. ... Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for

  • Lilly claims another EU okay for Taltz Lilly claims another EU okay for Taltz

    Lilly claims another EU okay for Taltz. The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients. ... Eli Lilly’s new immunotherapy Taltz has picked up a second indication in Europe, with the EMA approving the IL-17

  • Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

    The two trials - SURPASS and EXCEED - will compare interleukin-17 antagonist Cosentyx (secukinumab) against TNF blocker adalimumab in ankylosing spondylitis and psoriatic arthritis, respectively. ... Cosentyx was the first IL-17 inhibitor to reach the

  • Janssen’s Tremfya cleared for European use Janssen’s Tremfya cleared for European use

    therapy. The drug is a follow-up for its IL-23/IL-12 inhibitor Stelara, which is facing competition from newer psoriasis drugs showing greater efficacies in clinical trials. ... However, only 49.7% and 46.8% of patients taking Humira achieved a PASI 90,

  • AbbVie risankizumab trials set up psoriasis filing - and a market battle AbbVie risankizumab trials set up psoriasis filing - and a market battle

    The last couple of years have seen a number of new psoriasis drugs reach the market that have outperformed Stelara and TNF blockers in trials, including Novartis IL-17 inhibitor Cosentyx ... Since its debut in 2015 Cosentyx has been joined by IL-17

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics